Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals

AYGEN, Bilgehan; Canatan, Halit; taheri, serpil; YILDIZ, Orhan; KORKMAZ, Keziban; ZARARSIZ, Gökmen

Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals

Serpil TAHERİ, (Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Kayseri, Türkiye)

Bilgehan AYGEN, (Erciyes Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Kayseri, Türkiye)

Keziban KORKMAZ, (Erciyes Üniversitesi, Tıp Fakültesi, Betül-Ziya Eren Genom ve Kök Hücre Merkezi, Kayseri, Türkiye)

Orhan YILDIZ, (Erciyes Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Kayseri, Türkiye)

Gökmen ZARARSIZ, (Erciyes Üniversitesi, Tıp Fakültesi, Biyoistatistik Anabilim Dalı, Kayseri, Türkiye)

Halit CANATAN (Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Kayseri, Türkiye)

Balkan Medical Journal

1 0

Yıl: 2015 Cilt: 32 Sayı: 2 Sayfa Aralığı: 147 - 155 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals

Öz:

Background: Host genetic factors can affect the prog- ress of hepatitis-C virus (HCV) infection. Interleukin- 28B (IL28B) single nucleotide polymorphisms mayplay an important role in the clearance of HCV sponta- neously or with treatment. Aims: The aim of our study was to evaluate the rateof IL28B genotypes in patients with Chronic Hep- atitis-C (CHC) and healthy control subjects and toexamine the characteristics of patients in each IL28Bsubgroup. Study Design: Case-control study. Methods: IL28B polymorphisms were genotypedby Polymerase Chain Reaction and Restriction Frag- ment Length Polymorphism (PCR-RFLP) in all sub-jects. Results: The mean age was 52.3±10.9 years (33% fe- male) in the CHC patients and 52.5±11.5 years (39.1%female) in the healthy controls. The percentage of pa- tients with a high baseline viral load (≥400,000 IU/mL)was higher in the CT group (69.8%) compared to the C/C (44.4%) and T/T (50%) groups (p=0.021). Therewas no significant difference in liver fibrosis and livernecroinflammation distribution among the CC, CT andTT genotypes with mild, moderate and severe groups(p=0.058 and p=0.791, respectively). Mean age, gen-der ratio, body mass index, viral load at baseline, rateof HCV genotypes, baseline ALT levels were not sig-nificantly different among the three IL28B subgroups(p>0.05). A significant increase was observed in thefrequencies of IL28B rs12979860 TT genotypes in theCHC patients (20.6%) compared to the healthy controlgroup (8.7%) (p=0.033).Conclusion: In the patients with chronic HCV-genotype1b and 4 infections, the IL28B rs12979860 (C>T) genepolymorphism frequency of the TT genotype and T allelewas higher than in healthy control subjects. This resultindicates that the TT genotype may be more effective inthe progression of HCV infection than other genotypes.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Aygen B. Hepatitis C. Turkiye Klinikleri J Int Med Sci 2006;2:21- 33.
2. Aygen B. Kronik hepatit Cde tedavi ve izlem: In: Köksal İ, Leblebicioğlu H, editors. Kronik Hepatitlerin Tanı ve Te - davisinde Güncel Yaklaşımlar. 1st ed. Ankara: Bilimsel Tıp Yayınevi; 2009;223-33.
3. Bozkurt I, Aygen B, Gökahmetoglu S, Yildiz O. Hepatitis C and Occult Hepatitis C Infection among Hemodialysis Patients from Central Anatolia. J Pure Appl Microbiol 2014:8:435-40.
4. Bozkurt I, Aygen B, Gökahmetoglu S, Yildiz O. Frequency and epidemiologic characteristics of hepatitis C virus infection in patients receiving hemodialysis in our region. Klimik Journal 2012;25:19-23. [CrossRef]
5. Mıstık R, Türkiyede viral hepatit epidemiyolojisi: yayınların irdelenmesi. In: Tabak F, Balik I, Tekeli E, editors. Viral Hepatit 2007. 1st ed. Ankara: Oban Matbaası; 2007;9-50.
6. Ökten A. Türkiyede kronik hepatit, siroz ve hepatosellüler karsinoma etiyolojisi. Güncel Gastroenterol Derg 2003;7:187- 91.
7. Gökahmetoğlu S, Bozdayı M, Özbakır Ö, Aygen B, Özbal Y, Soyuer I, Yildiz O. Hepatitis C virus genotypes detected in Erci- yes University. J Turk Microbiol Soc 2007;37:35-8.
8. Gökahmetoğlu S, Atalay MA, Kılınç A. Determination of the hepatitis C virus genotypes with pyrosequencing method. Er - ciyes Med J 2011;33:99-102.
9. Aygen B, Yıldız O, Çaylan R, Köksal I, Saltoğlu N, Taşova Y, Leblebicioğlu H, et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C patients: results of a multicenter clinical trial. Viral Hepatitis Journal 2004;9:123-9.
10. Yıldız O, Aygen B, Alp E, Gökahmetoğlu S, Soyuer I. Retro - spective evaluation of different antiviral treatments for chronic hepatitis C infection. FLORA 2008;13:122-9.
11. Aygen, B, Yıldız O, Bostancı F, Özbakır Ö, Gökahmetoğlu S, Patıroğlu TE. A comparison of interferon-alpha-2b induction ther- apy with interferon-alpha-2b plus ribavirin combination therapy for the treatment of chronic hepatitis C. FLORA 2004;9:189-99.
12. Demiraslan H, Aygen B, Yıldız O, Soyuer I, Gökahmetoğlu S. A comparison of interferon α-2a plus ribavirin combination therapy with peginterferon α-2a plus ribavirin combination therapy for treat- ment of chronic hepatitis C. Viral Hepatitis Journal 2008;13:12-22.
13. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45. [CrossRef]
14. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, OHuigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801. [CrossRef]
15. Fonseca-Coronado S, Vaughan G, Cruz-Rivera MY, Carpio-Pe- droza JC, Ruiz-Tovar K, Ruiz-Pacheco JA, et al. Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hep- atitis C patients. J Clin Microbiol 2011;49:2706-10. [CrossRef]
16. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011;6:e17232. [CrossRef]
17. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 2009;461:399-401. [CrossRef]
18. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010;52:1216-24. [CrossRef]
19. Sporea I, Popescu A , Curescu M, Sirli R, Dan I, Goldis A, et al. The correlation of Il28B Genotype with sustained virologic response in Romanian patients with chronic hepatitis C. Hepat Mon 2011;11:975-9. [CrossRef]
20. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44. [CrossRef]
21. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, et al. APASL consensus statements and management algorithms for hep- atitis C virus infection. Hepatol Int 2012;6:409-35. [CrossRef]
22. Ishak K, Baptisa A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9. [CrossRef]
23. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, et al. Role of interleukin 28B rs12979860 C/T polymor- phism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol 2011;31:891-9. [CrossRef]
24. El Awady MK, Noha El Din NGB, Tabll A, El Hosary Y, Abdel Aziz AO, El Khayat H, et al. IL28B polymorphism and cytomega- lovirus predict response to treatment in Egyptian HCV type 4 pa- tients. World J Gastroenterol 2013;19:290-8. [CrossRef]
25. Tozun N, Ozdogan OC, Cakaloglu Y, İdilman R, Karasu Z, Akarca U, et al. Nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology 2010;52(Suppl 1):697.
26. Özer B, Seydaoğlu G, Özşahın AK, Demırhındı H. Risk factors for higher anti-HCV positivity in a border city in southern Tur- key with unique population characteristics. Turk J Gastroenterol 2012;23:574-9.
27. Yildirim B, Barut S, Bulut Y, Yenişehirli G, Ozdemir M, Cetin I, et al. Seroprevalence of hepatitis B and C viruses in the province of Tokat in the Black Sea region of Turkey: A population-based study. Turk J Gastroenterol 2009;20:27-30.
28. Simsek H, Alp A, Yilmaz B, Balabana YH, Altun B, Uzun O, et al. The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C. Eur J Gastroenterol Hepatol 2012;24:1113-6. [CrossRef]
29. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010;363:166-76. [CrossRef]
30. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011;60:1284-93. [CrossRef]
31. El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, El Din NGB, Zayed N, et al. Association of IL28B SNP with progres- sion of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon 2012;12:271-7. [CrossRef]
32. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, Gu LL, et al. Asso- ciation of genetic variation in IL28B with hepatitis C treatment- induced viral clearance in the Chinese Han population. Antivir Ther 2011;16:141-7. [CrossRef]
33. da Silva Conde SR, Soares Monteiro JC, Silva Dos Santos BT, Fonseca Filgueiras NK, de Almeida Lins PA, Bonfim Freitas F, et al. SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treat- ment. Biomed Res Int 2014;2014:748606. [CrossRef]
34. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rueda PM, Quiles-Perez R, Gila-Medina A, Casado J, et al. Ge- netic variation in interleukin 28B with respect to vertical trans- mission of hepatitis C virus and spontaneous clearance in HCV- infected children. Hepatology 2011;53:1830-8. [CrossRef]
35. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 2011;54:716-22. [CrossRef]
36. Pasha HF, Radwan MI, Hagrass HA, Tantawy EA, Emara MH. Cytokines genes polymorphisms in chronic hepatitis C: Impact on susceptibility to infection and response to therapy. Cytokine 2013;61:478-84. [CrossRef]
37. Shaker OG, Sadik NAH. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated inter- feron/ribavirin-therapy. J Gastroenterol Hepatol 2012;27:1842-9. [CrossRef]
38. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-14. [CrossRef]
39. Montes-Cano M, Garcia-Lozano J, Abad-Molina C, Romero- Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010;52:33-7. [CrossRef]
40. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4. [CrossRef]
41. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver Int 2011;31(Suppl 1):29-35. [CrossRef]

APA	taheri s, AYGEN B, KORKMAZ K, YILDIZ O, ZARARSIZ G, Canatan H (2015). Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. , 147 - 155.
Chicago	taheri serpil,AYGEN Bilgehan,KORKMAZ Keziban,YILDIZ Orhan,ZARARSIZ Gökmen,Canatan Halit Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. (2015): 147 - 155.
MLA	taheri serpil,AYGEN Bilgehan,KORKMAZ Keziban,YILDIZ Orhan,ZARARSIZ Gökmen,Canatan Halit Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. , 2015, ss.147 - 155.
AMA	taheri s,AYGEN B,KORKMAZ K,YILDIZ O,ZARARSIZ G,Canatan H Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. . 2015; 147 - 155.
Vancouver	taheri s,AYGEN B,KORKMAZ K,YILDIZ O,ZARARSIZ G,Canatan H Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. . 2015; 147 - 155.
IEEE	taheri s,AYGEN B,KORKMAZ K,YILDIZ O,ZARARSIZ G,Canatan H "Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals." , ss.147 - 155, 2015.
ISNAD	taheri, serpil vd. "Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals". (2015), 147-155.

APA	taheri s, AYGEN B, KORKMAZ K, YILDIZ O, ZARARSIZ G, Canatan H (2015). Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. Balkan Medical Journal, 32(2), 147 - 155.
Chicago	taheri serpil,AYGEN Bilgehan,KORKMAZ Keziban,YILDIZ Orhan,ZARARSIZ Gökmen,Canatan Halit Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. Balkan Medical Journal 32, no.2 (2015): 147 - 155.
MLA	taheri serpil,AYGEN Bilgehan,KORKMAZ Keziban,YILDIZ Orhan,ZARARSIZ Gökmen,Canatan Halit Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. Balkan Medical Journal, vol.32, no.2, 2015, ss.147 - 155.
AMA	taheri s,AYGEN B,KORKMAZ K,YILDIZ O,ZARARSIZ G,Canatan H Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. Balkan Medical Journal. 2015; 32(2): 147 - 155.
Vancouver	taheri s,AYGEN B,KORKMAZ K,YILDIZ O,ZARARSIZ G,Canatan H Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals. Balkan Medical Journal. 2015; 32(2): 147 - 155.
IEEE	taheri s,AYGEN B,KORKMAZ K,YILDIZ O,ZARARSIZ G,Canatan H "Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals." Balkan Medical Journal, 32, ss.147 - 155, 2015.
ISNAD	taheri, serpil vd. "Characterization of the interleukin-28b gene rs12979860 c/t polymorphism in Turkish chronic hepatitis c patients and healthy ındividuals". Balkan Medical Journal 32/2 (2015), 147-155.